E-viri
Recenzirano
-
Farina, Elisa; Loglio, Alessandro; Tosetti, Giulia; Degasperi, Elisabetta; Viganò, Mauro; Gentile, Carmine; Monico, Sara; Perbellini, Riccardo; Borghi, Marta; Facchetti, Floriana; Sara Colonia Uceda Renteria; Ceriotti, Ferruccio; Cerini, Federica; Primignani, Massimo; Lampertico, Pietro
Alimentary pharmacology & therapeutics, 06/2023, Letnik: 57, Številka: 12Journal Article
BackgroundLong‐term administration of TDF/ETV in patients with HBV‐related compensated cirrhosis reduces HCC and decompensation events but the effect of this regimen on development/regression of oesophageal varices (EV) is currently unknown.AimTo assess the risk of EV development/progression in this population.MethodsA total of 186 Caucasian HBV‐monoinfected compensated cirrhotics were enrolled in a long‐term cohort study from TDF/ETV introduction. Upper GI endoscopies were performed according to Baveno recommendations. Primary endpoint was development/progression of oesophageal/gastric varices over time.ResultsAt TDF/ETV start, median age was 61 years, 80% males, 60% HBV‐DNA undetectable, 63% NUCs previously exposed, 73% normal ALT, 40% platelets <150,000/mmc and 25 (13%) with low‐risk varices (LRV). During 11 years of antiviral therapy and 666 endoscopies performed, 9 patients either developed or had a progression of oesophageal or gastric varices with an 11‐year cumulative probability of 5.1% (95% CI 3–10%); no patient bled. Out of 161 patients without EV at baseline, the 11‐year probably was 4.5% with all varices developing within the first six years of treatment. In 25 patients with LRV at baseline, the 11‐year probability of progression or regression was 9.3% and 58%, respectively. Only baseline platelet count (HR 0.96, p = 0.028) was associated with LRV development at multivariate analysis: platelet ≤90,000/mmc (AUROC 0.70) had 98.1% specificity, 42.9% sensitivity, 50% PPV for LRV onset.ConclusionsIn compensated cirrhotic patients under long‐term effective TDF/ETV treatment, the 11‐year risk of developing/progressing EV is negligible, thus challenging the current endoscopic surveillance recommendations in patients without EV at baseline.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.